Figure 6.

Effect of soluble Fas ligand (sFasL) on neovascularization in vivo. Matrigel containing vascular endothelial growth factor (VEGF)₁₆₅ and heparin were injected subcutaneously with or without sFasL (100 ng/ml) into the abdomen of C57BL/6 mice. After 14 days, the mice were sacrificed and the Matrigel plugs were excised and fixed. (a) Representative Matrigel plugs containing PBS (none), VEGF₁₆₅ (500 ng/ml), or VEGF₁₆₅ (500 ng/ml) plus sFasL (100 ng/ml). (b) Quantification of new vessel formation via measurements of the hemoglobin (Hb) content within the Matrigel is shown. Eight mice were used for each group. Data represent the mean ± standard deviation, and similar results were obtained with two different experiments. *P < 0.001 versus the Hb content of the Matrigel containing VEGF₁₆₅. (c) Representative photograph of the gels shown in cross-section and stained with hematoxylin and eosin. Original magnification (×100).